Clinical trials: Development, Adolescent
Behavioral Symptoms, Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00337571
- Testing
- Aripiprazole
- Where
- 31 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism
Safety of L1-79 in Adolescent and Adult Males With Autism
This is a five-arm designed to assess the safety of L1-79 that incorporates 15 prospectively randomized, placebo controlled patients and 5 open label patients at either 100 tid (three times daily) or 200 tid dosing for 28 days.
- Trial name
- NCT02947048
- Testing
- L1-79
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Yamo Pharmaceuticals LLC
Tuberous Sclerosis Complex
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
- Trial name
- NCT05059327
- Where
- 27 sites in United States, India and 6 more
- Volunteers
- 61 people
- Sponsor
- Noema Pharma AG
Osteogenesis Imperfecta
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product…
- Trial name
- NCT07366086
- Testing
- Vitamin D, Calcium
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 71 people
- Sponsor
- Amgen
Obsessive Compulsive Disorder
Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
To evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) with a diagnosis of anxiety…
- Trial name
- SPRITES (NCT01302080)
- Testing
- sertraline, psychotherapy
- Where
- 44 sites in United States
- Volunteers
- 941 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Growth Hormone Deficiency
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.
- Trial name
- TAUBER (NCT00156143)
- Testing
- Blood sample, Radiography
- Volunteers
- 90 people
- Sponsor
- Pfizer
Vaping, E Cig Use
A Hybrid Program to Prevent Substance Use Risk Among Upper Elementary School Students Using a Positive Youth Development Approach
The goal of this randomized controlled trial is to evaluate a psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription…
- Conditions
- Vaping, E Cig Use, Prescription Drug Misuse
- Trial name
- NCT07162155
- Testing
- School-based Hybrid Intervention to Prevent Vaping and Prescription Drug Misuse
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is generally safe and well tolerated in…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190267
- Testing
- asenapine
- Volunteers
- 204 people
- Sponsor
- Organon and Co
Growth Disorders
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and…
- Trial name
- NCT00330668
- Testing
- rh IGF-1 (mecasermin)
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Ipsen
Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome
IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
STUDY OBJECTIVE To evaluate the safety, tolerability, and efficacy, as growth velocity (statural growth), of rhIGF-I/rhIGFBP-3 administered for 12 months in pre-pubertal children and adolescents with GHIS.
- Trial name
- NCT00368173
- Testing
- rhIGF-I/rhIGFBP-3
- Where
- 15 sites in United States, Argentina and 12 more
- Sponsor
- Insmed Incorporated
Achondroplasia
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia.
- Trial name
- teACH (NCT06732895)
- Testing
- Navepegritide
- Where
- 5 sites in Canada, Denmark and 3 more
- Volunteers
- 25 people
- Sponsor
- Ascendis Pharma A/S
Autistic Disorder
An Evaluation of Low Level Laser Light Therapy for Autistic Disorder
The purpose of this study is to determine whether the Erchonia HLS Laser is effective in the treatment of irritability associated with autistic disorder in children and adolescents aged five (5) to seventeen (17) years.
- Trial name
- NCT03379662
- Testing
- Erchonia HLS Laser
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Erchonia Corporation
Autism Spectrum Disorder, Social Communication Disorder
To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD
The purpose of this study is to demonstrate the superiority of the treatment of cognitive therapy software 'NDTx-01' compared to TAU (Treatment-As-Usual).
- Trial name
- NCT06446193
- Testing
- NDTx-01, TAU
- Where
- 5 sites in South Korea
- Volunteers
- 86 people
- Sponsor
- Neudive Inc.
Achondroplasia
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
TransCon CNP administered once-weekly in children and adolescents with achondroplasia who have completed a prior TransCon CNP clinical trial.
- Trial name
- AttaCH (NCT05929807)
- Testing
- TransCon CNP
- Where
- 19 sites in United States, Australia and 10 more
- Volunteers
- 140 people
- Sponsor
- Ascendis Pharma Growth Disorders A/S
Autism Spectrum Disorder (ASD)
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
- Trial name
- NCT06757504
- Testing
- TTYP01 Tablets (12mg or 18mg)
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Autism Spectrum Disorder
A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
The purpose of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of Autism Spectrum Disorder (ASD) during 12 weeks of treatment using the Autism Behavior Inventory (ABI).
- Trial name
- Envision (NCT03664232)
- Testing
- JNJ-42165279
- Where
- 9 sites in United States
- Volunteers
- 78 people
- Sponsor
- Janssen Research & Development, LLC
Osteogenesis Imperfecta
Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with Osteogenesis Imperfecta (OI).
- Trial name
- NCT04545554
- Testing
- Romosozumab, Calcium, Vitamin D
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 25 people
- Sponsor
- Amgen
Substance-related Disorders, Alcohol-Related Disorders
LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School
LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.
- Conditions
- Substance-related Disorders, Alcohol-Related Disorders, Tobacco Use Disorder, Marijuana Use
- Trial name
- NCT07655609
- Testing
- Introduction, Norms re: Protective Behavior Strategies (PBS), Life Skills
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Prevention Strategies, LLC
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Irritability Associated With Autism Spectrum Disorder
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
- Trial name
- NCT07284745
- Testing
- KarXT, KarX-EC
- Where
- 39 sites in United States, Australia and 2 more
- Volunteers
- 176 people
- Sponsor
- Bristol-Myers Squibb